Graphite Bio discontinues sickle cell gene therapy nula-cel, begins strategic review, reports FY2022 net loss $101.1M

LENZ Therapeutics, Inc.

Discontinued development of nula-cel for sickle cell disease after serious adverse event (pancytopenia) in first dosed patient.
Initiated process to evaluate strategic alternatives; corporate restructuring to preserve capital while conducting review.
FY2022 net loss $101.1M ($1.84/share); cash and equivalents $283.6M as of Dec 31, 2022.
Voluntarily paused Phase 1/2 CEDAR study of nula-cel in Jan 2023 due to treatment-related pancytopenia.
Intends to continue research on early-stage non-genotoxic conditioning program toward potential development candidates.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

LENZ Therapeutics, Inc. reported Fourth quarter and fiscal year 2022 results: net income Net loss was $24.6 million for the fourth quarter of 2022; Net loss was $101.1 million for fiscal year 2022, EPS $0.44 per basic and diluted share for the fourth quarter of 2022; $1.84 per basic and diluted share for fiscal year 2022.

Period: Fourth quarter and fiscal year 2022
Net income: Net loss was $24.6 million for the fourth quarter of 2022; Net loss was $101.1 million for fiscal year 2022
EPS: $0.44 per basic and diluted share for the fourth quarter of 2022; $1.84 per basic and diluted share for fiscal year 2022
Result: reported results

Exact text from the filing

Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

LENZ Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-008761

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.